Основная статистика
| LEI | 529900ENQUXMC5EBKO36 |
| CIK | 1339970 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to aTyr Pharma, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation |
|
| August 8, 2025 |
Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. SAN DIEGO – August 7, 2025 – aTyr Pharma, Inc. (Nasdaq: ATYR) |
|
| August 7, 2025 |
Form of Indenture, by and between the Registrant and one or more trustees to be named Exhibit 4.9 aTyr Pharma, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 20 Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 7 Sectio |
|
| August 7, 2025 |
2022 Inducement Plan, as amended Exhibit 10.2 aTyr Pharma, Inc. 2022 Inducement Plan Adopted by the Compensation Committee: March 21, 2022 Amended by the Compensation Committee: March 21, 2025 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if appl |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. SAN DIEGO – August 7, 2025 – aTyr Pharma, Inc. (Nasdaq: ATYR) |
|
| August 7, 2025 |
Calculation of Filing Fee Table Form S-8 (Form Type) aTyr Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2015 Stock Option and Incentive Plan, as ame |
|
| August 7, 2025 |
As filed with the U.S. Securities and Exchange Commission on August 7, 2025 As filed with the U.S. Securities and Exchange Commission on August 7, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction of incorporation or organization) (I.R.S. E |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) aTyr Pharma, Inc. |
|
| August 7, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.12 aTyr Pharma, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of aTyr Pharma, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PH |
|
| August 7, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.14 aTyr Pharma, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of atyr pharma, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the |
|
| August 7, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.13 aTyr Pharma, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of aTyr Pharma, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 7, 2025 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR P |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 6, 2025 |
2015 Stock Option Plan and Incentive Plan, as amended Exhibit 10.1 ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN (as amended) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation (the “Comp |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 13, 2025 |
aTyr Pharma, Inc. Statement of Company Policy on Insider Trading and Disclosure Exhibit 19.1 ATYR PHARMA, INC. Statement of Company POLICY on Insider Trading and Disclosure May 6, 2015, as updated on October 28, 2015 and November 4, 2021 This memorandum sets forth the policy of aTyr Pharma, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Stat |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 13, 2025 |
aTyr Pharma, Inc. Special Trading Procedures for Designated Individuals Exhibit 19.2 ATYR PHARMA, INC. SPECIAL TRADING PROCEDURES FOR DESIGNATED INDIVIDUALS To comply with federal and state securities laws governing insider trading, aTyr Pharma, Inc. (the “Company”) has adopted these Special Trading Procedures for Designated Individuals (“Trading Procedures”) as an addendum to the Company’s Statement of Company Policy on Insider Trading and Disclosure (the “Insider Tr |
|
| March 13, 2025 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37378 ATYR PHARMA, I |
|
| January 8, 2025 |
EXHIBIT “3” POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints J. |
|
| January 8, 2025 |
AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934: 1. |
|
| January 8, 2025 |
ITEM 3 CLASSIFICATION OF REPORTING PERSONS Identity and Classification of Each Reporting Person EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS Identity and Classification of Each Reporting Person IDENTITY CLASSIFICATION UNDER ITEM 3 Federated Hermes Equity Funds (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U. |
|
| January 8, 2025 |
EXHIBIT “3” POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints J. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 23, 2024 |
Exhibit 1.1 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM December 23, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by aTyr Pharma, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), who are parties |
|
| December 23, 2024 |
aTyr Pharma, Inc. Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275455 PROSPECTUS SUPPLEMENT (To Prospectus dated November 20, 2023) aTyr Pharma, Inc. Up to $150,000,000 Common Stock This prospectus supplement amends and restates the information in our prospectus supplement dated November 9, 2023 and, accordingly, the information in this prospectus supplement supersedes the information contained in that pro |
|
| December 12, 2024 |
ATYR PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 99.1 ATYR PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of aTyr Pharma, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company. In |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 14, 2024 |
ATYR / aTyr Pharma, Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 atyr13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) aTyr Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2024 |
f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 AT |
|
| November 7, 2024 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstra |
|
| October 15, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-2974exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without t |
|
| October 15, 2024 |
ATYR / aTyr Pharma, Inc. / Point72 Asset Management, L.P. - ATYR PHARMA, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 002120202 (CUSIP Number) October 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| October 7, 2024 |
ATYR / aTyr Pharma, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this St |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| August 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) aTyr Pharma, Inc. |
|
| August 13, 2024 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the sec |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PH |
|
| August 13, 2024 |
As filed with the U.S. Securities and Exchange Commission on August 13, 2024 As filed with the U.S. Securities and Exchange Commission on August 13, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction of incorporation or organization) (I.R.S. |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 18, 2024 |
June 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Lynn Dicker Kevin Kuhar Re: aTyr Pharma, Inc. Form 10-K for fiscal Year Ended December 31, 2023 File No. 001-37378 Dear Lynn Dicker and Kevin Kuhar: We are writing in response to the comment received from the staff (the “Staff”) of |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 29, 2024 |
aTyr Pharma, Inc. Code of Business Conduct and Ethics, as amended Exhibit 14.1 ATYR PHARMA, INC. Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. (the “we”, “us”, “our” or the “Company”) established this Code of Business Conduct and Ethics (this “Code”) to aid the Company’s directors, officers and employees in making ethical and legal decisions when conducting the Company’s business and performing the |
|
| May 29, 2024 |
aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended Exhibit 10.1 ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN (as amended) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation (the “Comp |
|
| May 2, 2024 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equiv |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR P |
|
| May 2, 2024 |
First Amendment to Lease Between the Registrant and San Diego, Creekside, LLC, dated April 8, 2024 EX-10.1 2 life-ex101.htm EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO lease BETWEEN SAN DIEGO CREEKSIDE, LLC AND aTYR PHARMA, INC. THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is effective as of June 1, 2023, by and between SAN DIEGO CREEKSIDE, LLC, a Delaware limited liability company (“Landlord”), and aTYR PHARMA, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are partie |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 14, 2024 |
aTyr Pharma, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 aTyr Pharma, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of aTyr Pharma, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Ince |
|
| March 14, 2024 |
Non-Employee Director Compensation Policy EXHIBIT 10.19 ATYR PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of aTyr Pharma, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company. I |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37378 ATYR PHARMA, I |
|
| March 14, 2024 |
Exhibit 4.6 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of aTyr Pharma, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law (DGCL). This information is qualified entirely by reference to the app |
|
| March 14, 2024 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Acce |
|
| February 14, 2024 |
LIFE / aTyr Pharma, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2024 |
LIFE / aTyr Pharma, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 atyr13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001per share (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 18, 2024 |
LIFE / aTyr Pharma, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 life1571-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2023 (Date of Event Whic |
|
| January 2, 2024 |
LIFE / aTyr Pharma, Inc. / Logos Global Management LP Passive Investment SC 13G 1 atyr13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) aTyr Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) December 19, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 16, 2023 |
aTyr Pharma, Inc. 10240 Sorrento Valley Road, Suite 300 San Diego, CA, 92121 aTyr Pharma, Inc. 10240 Sorrento Valley Road, Suite 300 San Diego, CA, 92121 November 16, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: aTyr Pharma, Inc. Registration Statement on Form S-3 (File No. 333-275455) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rul |
|
| November 9, 2023 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiat |
|
| November 9, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.14 aTyr Pharma, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of atyr pharma, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the |
|
| November 9, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.12 aTyr Pharma, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of aTyr Pharma, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR |
|
| November 9, 2023 |
aTyr Pharma, Inc. Up to $47,836,381 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-263585 PROSPECTUS SUPPLEMENT (To Prospectus dated April 8, 2022) aTyr Pharma, Inc. Up to $47,836,381 Common Stock This prospectus supplement amends and restates the information in our prospectus supplement dated April 22, 2022 and, accordingly, the information in this prospectus supplement supersedes the information contained in that prospectus |
|
| November 9, 2023 |
Form of Indenture, by and between the Registrant and one or more trustees to be named Exhibit 4.9 aTyr Pharma, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 20 Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 7 Sectio |
|
| November 9, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.13 aTyr Pharma, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Exhibit 4.13 aTyr Pharma, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existi |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) aTyr Pharma, Inc. |
|
| September 26, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 26, 2023 |
The Evolutionary Intelligence Biotech September 2023 Exhibit 99.1 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) aTyr Pharma, Inc. |
|
| August 10, 2023 |
As filed with the U.S. Securities and Exchange Commission on August 10, 2023 As filed with the U.S. Securities and Exchange Commission on August 10, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction of incorporation or organization) (I.R.S. |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARM |
|
| August 9, 2023 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs [email protected] aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in |
|
| May 19, 2023 |
aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended Exhibit 10.1 ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN (as amended) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation (the “Comp |
|
| May 19, 2023 |
Certificate of Amendment to Restated Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF ATYR PHARMA, INC. aTyr Pharma, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: That the name of the Corporation is aTyr Pharma, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 19, 2023 |
aTyr Pharma, Inc. Code of Business Conduct and Ethics, as amended Exhibit 14.1 ATYR PHARMA, INC. Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. (the “we”, “us”, “our” or the “Company”) established this Code of Business Conduct and Ethics (this “Code”) to aid the Company’s directors, officers and employees in making ethical and legal decisions when conducting the Company’s business and performing the |
|
| May 9, 2023 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patien |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR P |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 29, 2023 |
DEF 14A 1 2023proxystatment.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commis |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 14, 2023 |
Description of Common Stock of the Registrant Exhibit 4.9 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of aTyr Pharma, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law (DGCL). This information is qualified entirely by reference to the app |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37378 ATYR PHARMA, I |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 9, 2023 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in p |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 22, 2023 |
LIFE / Atyr Pharma Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 002120202 (CUSIP Number) February 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 17, 2023 |
LIFE / aTyr Pharma Inc / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 atyrpharma.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001per share (Title of Class of Securities) 002120202 (CUSIP Number) February 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2023 |
LIFE / aTyr Pharma Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* aTyr Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2023 |
Underwriting Agreement by and between aTyr Pharma, Inc. and RBC Capital Markets, LLC Exhibit 1.1 22,225,000 Shares ATYR PHARMA, INC. Common Stock UNDERWRITING AGREEMENT February 8, 2023 RBC CAPITAL MARKETS, LLC As Representative of the several Underwriters named in Schedule I hereto c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281 Ladies and Gentlemen: aTyr Pharma, Inc., a Delaware corporation (the “Company”), proposes to sell to t |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| February 9, 2023 |
22,225,000 Shares aTyr Pharma, Inc. Common Stock 424B5 1 cdpofinalprosupp.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-263585 PROSPECTUS SUPPLEMENT (To Prospectus dated April 8, 2022) 22,225,000 Shares aTyr Pharma, Inc. Common Stock We are offering 22,225,000 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol “LIFE”. The last reported sale price of our common stock on the Nasda |
|
| February 8, 2023 |
Subject to completion, dated February 8, 2023 424B5 1 cdpoprosupp.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-263585 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an of |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| February 1, 2023 |
LIFE / aTyr Pharma Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form819.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2022 (Date of Event Which Requ |
|
| November 14, 2022 |
Restated Certificate of Incorporation of the Registrant Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF aTYR PHARMA, INC. aTyr Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the ? Corporation ?), hereby certifies as follows: 1. The name of the Corporation is aTyr Pharma, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was Sept |
|
| November 14, 2022 |
Amended and Restated Bylaws of the Registrant Exhibit 3.6 AMENDED AND RESTATED BYLAWS OF aTYR PHARMA, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Corporation?s Board of Directors (the ?Board of Directors? |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 10, 2022 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards lar |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARM |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2022 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 17, 2022 |
A New Path to Medicine Company Reception May 16, 2022 Exhibit 99.1 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as ?may,? ?might,? ?will,? ?should,? ?expect,? ?plan,? ?anticipate,? ?believe,? |
|
| May 16, 2022 |
Lease dated May 12, 2022, by and between the Registrant and San Diego Creekside, LLC Exhibit 10.1 LEASE CREEKSIDE LABS SAN DIEGO CREEKSIDE, LLC, a Delaware limited liability company, as Landlord, and aTYR PHARMA, INC., a Delaware corporation, as Tenant. Table of Contents Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 6 2. LEASE TERM; OPTION TERM 7 3. BASE RENT 9 4. ADDITIONAL RENT 10 5. USE OF PREMISES 17 6. SERVICES AND UTILITIES 24 7. REPAIRS 28 8. ADDITIONS AND ALTERATIO |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 11, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) aTyr Pharma, Inc. |
|
| May 11, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 11, 2022 As filed with the U.S. Securities and Exchange Commission on May 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| May 10, 2022 |
aTyr Pharma, Inc. 2022 Inducement Plan Exhibit 10.3 aTyr Pharma, Inc. 2022 Inducement Plan Adopted by the Compensation Committee: March 21, 2022 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f+ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR P |
|
| May 10, 2022 |
Forms of Grant Notice and Stock Option Agreement under aTyr Pharma, Inc. 2022 Inducement Plan DOUBLE TRIGGER Exhibit 10.4 aTyr Pharma, Inc. Stock Option Grant Notice (2022 Inducement Plan) aTyr Pharma, Inc. (the ?Company?), pursuant to its 2022 Inducement Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Optio |
|
| May 9, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 9, 2022 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study |
|
| April 29, 2022 |
aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended Exhibit 10.1 ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN (as amended) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation (the ?Comp |
|
| April 29, 2022 |
aTyr Pharma, Inc. 2015 Employee Stock Purchase Plan, as amended Exhibit 10.2 ATYR PHARMA, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN The purpose of the aTyr Pharma, Inc. 2015 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of aTyr Pharma, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Common Stock?). Effec |
|
| April 29, 2022 |
Certificate of Amendment to Restated Certificate of Incorporation of the Registrant Exhibit 3.1 Certificate of Amendment to Restated Certificate of Incorporation of aTyr Pharma, Inc. aTyr Pharma, Inc. (the ?Corporation?), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: First: That the name of the Corporation is aTyr Pharma, Inc. The Corporation filed its original Certificate of Incorporation with the Secretary of State of |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 22, 2022 |
Up to $65,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-250095 PROSPECTUS SUPPLEMENT (To Prospectus dated November 23, 2020) Up to $65,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompan |
|
| April 22, 2022 |
Open Market Sale AgreementSM dated April 22, 2022 by and between the Registrant and Jefferies LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM April 22, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: aTyr Pharma, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 5, 2022 |
aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 April 5, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dorrie Yale Re: aTyr Pharma, Inc. Registration Statement on Form S-3 (File No. 333-263585) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 46 |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) aTyr Pharma, Inc. |
|
| March 15, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.13 aTyr Pharma, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Exhibit 4.13 aTyr Pharma, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existi |
|
| March 15, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.12 aTyr Pharma, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of aTyr Pharma, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37378 ATYR PHARMA, I |
|
| March 15, 2022 |
/s/As filed with the Securities and Exchange Commission on March 15, 2022 /s/As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 15, 2022 |
Exhibit 4.14 aTyr Pharma, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of atyr pharma, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the |
|
| March 15, 2022 |
ATYR PHARMA, INC. Code of Business Conduct and Ethics Exhibit 14.1 ATYR PHARMA, INC. Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. (the ?Company?) established this Code of Business Conduct and Ethics (this ?Code?) to aid the Company?s directors, officers and employees in making ethical and legal decisions when conducting the Company?s business and performing their day-to-day duties. The |
|
| March 15, 2022 |
EXHIBIT 10.20 ATYR PHARMA, INC. Common Stock ($0.001 par value per share) Capital on Demand? Sales Agreement March 23, 2021 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 Ladies and Gentlemen: aTyr Pharma, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or thro |
|
| March 15, 2022 |
Form of Indenture, by and between the Registrant and one or more trustees to be named Exhibit 4.9 aTyr Pharma, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table of Contents Page article 1 DEFINITIONS1 Section 1.01 Definitions of Terms.1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES5 Section 2.01 Designation and Terms of Securities.5 Section 2.02 Form of Securities and Trustee?s Certificate.7 Section 2.0 |
|
| March 14, 2022 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarte |
|
| March 14, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 4, 2022 |
PRE 14A 1 life-pre14a20220426.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm |
|
| February 14, 2022 |
LIFE / aTyr Pharma Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm226174d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* aTyr Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appro |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| February 14, 2022 |
LIFE / aTyr Pharma Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
LIFE / aTyr Pharma Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Sta |
|
| February 14, 2022 |
LIFE / aTyr Pharma Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* aTYR PHARMA, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 14, 2022 |
LIFE / aTyr Pharma Inc / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC |
|
| November 10, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platfor |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 8, 2021 |
LIFE / aTyr Pharma Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120103 (CUSIP Number) September 30, 2021 (Date of Event Which Requires Filing of this St |
|
| September 27, 2021 |
LIFE / aTyr Pharma Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* aTyr Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) September 16, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t |
|
| September 17, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of aTyr Pharma, Inc. and further agree to the filing of this Joint Filing Agreement as an exhib |
|
| September 17, 2021 |
LIFE / aTyr Pharma Inc / Ikarian Capital, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* aTYR PHARMA, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120202 (CUSIP Number) September 16, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| September 17, 2021 |
JOINT FILING AGREEMENT September 17, 2021 EXHIBIT 99.1 JOINT FILING AGREEMENT September 17, 2021 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including |
|
| September 17, 2021 |
LIFE / aTyr Pharma Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 16, 2021 |
Exhibit 1.1 Execution Version 9,375,000 Shares ATYR PHARMA, INC. Common Stock PURCHASE AGREEMENT September 15, 2021 PIPER SANDLER & CO. RBC CAPITAL MARKETS, LLC As Representative of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor N |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 16, 2021 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2021) 424B5 1 life-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-258725 and 333-259571 PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2021) 9,375,000 Shares aTyr Pharma, Inc. Common Stock We are offering 9,375,000 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol “LIFE”. On September 15, 2021, the last reported sale price |
|
| September 16, 2021 |
aTyr Pharma Announces Pricing of $75 million Public Offering of Common Stock Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Pricing of $75 million Public Offering of Common Stock SAN DIEGO ? September 16, 2021 ? aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on nove |
|
| September 15, 2021 |
424B5 1 life-424b5.htm 424B5 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities and are not soliciting an of |
|
| September 15, 2021 |
As filed with the Securities and Exchange Commission on September 15, 2021 Registration No. |
|
| September 13, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid |
|
| September 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 13, 2021 |
A New Path to Medicine Results for Phase 1b/2a Study of ATYR1923 in Pulmonary Sarcoidosis SEPTEMBER 13, 2021 Exhibit 99. |
|
| August 19, 2021 |
aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 CORRESP 1 filename1.htm aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 August 19, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: aTyr Pharma, Inc. Registration Statement on Form S-3 (File No. 333-258725) Request for Acceleration of Effective Date Ladies and Ge |
|
| August 11, 2021 |
Form of Indenture, by and between the Registrant and one or more trustees to be names Exhibit 4.9 aTyr Pharma, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities INDENTURE Indenture, dated as of [?], 20, among aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [Trustee], as trustee (the ?Trustee?): Whereas, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the iss |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Ex |
|
| August 11, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021 Registration No. |
|
| August 11, 2021 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.13 aTyr Pharma, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Exhibit 4.13 aTyr Pharma, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existi |
|
| August 11, 2021 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.12 aTyr Pharma, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of aTyr Pharma, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| August 11, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.14 aTyr Pharma, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of atyr pharma, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between aTyr Pharma, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| August 10, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. |
|
| May 25, 2021 |
aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen SAN DIEGO ? May 25, 2021 ? aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathw |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (E |
|
| May 14, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 14, 2021 As filed with the U.S. Securities and Exchange Commission on May 14, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models |
|
| May 4, 2021 |
aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended Exhibit 10.1 ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN (as amended) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation (the ?Comp |
|
| May 4, 2021 |
Certificate of Amendment to Restated Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF ATYR PHARMA, INC. aTyr Pharma, Inc. (the ?Corporation?), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: That the name of the Corporation is aTyr Pharma, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of |
|
| May 4, 2021 |
8-K 1 life-8k20210428.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of inc |
|
| April 9, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120103 (CUSIP Number) March 31, 2021 (Date of Event Which Requires Filing of this Statem |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 24, 2021 |
Code of Business Conduct and Ethics, as amended Exhibit 14.1 ATYR PHARMA, INC. Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. (the ?Company?) established this Code of Business Conduct and Ethics (this ?Code?) to aid the Company?s directors, officers and employees in making ethical and legal decisions when conducting the Company?s business and performing their day-to-day duties. The |
|
| March 24, 2021 |
EXHIBIT 10.20 ATYR PHARMA, INC. Common Stock ($0.001 par value per share) Capital on Demand? Sales Agreement March 23, 2021 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 Ladies and Gentlemen: aTyr Pharma, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or thro |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37378 ATYR PHARMA, I |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 24, 2021 |
Up to $25,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-250095 PROSPECTUS SUPPLEMENT (to the Prospectus dated November 23, 2020) Up to $25,000,000 Common Stock We have entered into a Capital on DemandTM Sales Agreement dated March 23, 2021, or Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, relating to the shares of our common stock offered by this prospectus suppleme |
|
| March 24, 2021 |
Exhibit 10.19 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (the ?First Amendment?) is entered into effective as of February 5, 2021 (the ?Effective Date?) by and between aTyr Pharma, Inc., a Delaware corporation (the ?Company?) and Sanjay S. Shukla, M.D., M.S. ("Executive"). Whereas, Company and Executive entered into that certain Employment Agreement dated |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 23, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. Results from ATYR1923 clinical trial in pa |
|
| March 15, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR |
|
| March 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 17, 2021 |
EX-99.2 3 d135612dex992.htm EX-99.2 Exhibit 99.2 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Steven G. Martin, Christos Komissopoulos, Erik Brown, William Blank and Kathryn A. Wilson signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned statements on Schedule 13D or Sch |
|
| February 17, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 002120103 (CUSIP Number) February 12, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 17, 2021 |
EX-99.1 2 d135612dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of aTyr Pharma, Inc., and further agree that th |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) aTyr Pharma, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 002120103 (CUSIP N |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) ATYR PHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 002120103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Sta |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* aTyr Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 002120202 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 12, 2021 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) Altium Capital Management, LP SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| February 9, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231658 PROSPECTUS SUPPLEMENT (to the Prospectus dated June 20, 2019) Up to $2,991,000 Common Stock We previously entered into a common stock sales agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated May 21, 2019, as amended June 18, 2019 and November 13, 2020, relating to shares of our common stock offered b |
|
| February 9, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| January 25, 2021 |
Neuropilin-2 is Expressed on Immune Cells Present in the Tumor Microenvironment, and May Contribute to the Suppression of Immune Regulation leading to Progression and Metastasis of Cancer Samantha Tyler1, Michaela Ferrer1, Clara Polizzi1, Rodrigo Da Silva1, Lisa Eide1, Kendall Walwick1, Matt Seikkula1, Christoph Burkart1, Suzanne Paz1, Leslie Nangle1* 1aTyr Pharma, San Diego California *Corresponding author Abstract Results Introduction Experimental Procedures Fig 2. |
|
| January 25, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN |
|
| January 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| January 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| January 22, 2021 |
A Mass Spectrometry Proteomics-Based Approach to Identify Target Receptors for Novel Extracellular tRNA Synthetase Fragments Purpose: To identify target receptors and determine the biological functions of novel extracellular tRNA synthetase fragments with links to immune modulation Methods: tRNA synthetase fragments were expressed recombinantly, and their binding to various human cell lines was assessed by flow cytometry. |
|
| January 22, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 aTyr Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120103 (CUSIP Number) December 31, 2020 Date of Event |
|
| January 22, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Re |
|
| January 14, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan SAN DIEGO – January 14, 2021– aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of in |
|
| January 14, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| January 11, 2021 |
A New Path to Medicine January 2021 Exhibit 99.1 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “proj |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| January 4, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission File |
|
| January 4, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of |
|
| November 19, 2020 |
CORRESP 1 filename1.htm aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 November 19, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: David Gessert Re: aTyr Pharma, Inc. Registration Statement on Form S-3 (File No. 333-250095) Request of Acceleration of Effective Date Ladies and G |
|
| November 13, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.13 aTyr Pharma, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of atyr pharma, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the |
|
| November 13, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.12 aTyr Pharma, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Exhibit 4.12 aTyr Pharma, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existi |
|
| November 13, 2020 |
Form of Indenture, by and between the Registrant and one or more trustees to be names Exhibit 4.8 aTyr Pharma, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS1 Section 1.01 Definitions of Terms1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES5 Section 2.01 Designation and Terms of Securities5 Section 2.02 Form of Securities and Trustee’s Certificate8 Section 2.03 D |
|
| November 13, 2020 |
As filed with the Securities and Exchange Commission on November 13, 2020 Registration No. |
|
| November 13, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.11 aTyr Pharma, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of aTyr Pharma, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| November 13, 2020 |
Up to $10,500,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-231658 PROSPECTUS SUPPLEMENT (to the Prospectus dated June 20, 2019) Up to $10,500,000 Common Stock We previously entered into a common stock sales agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated May 21, 2019, as amended June 18, 2019 and November 13, 2020, relating to shares of our common stock offered |
|
| November 13, 2020 |
Exhibit 10.1 AMENDMENT NO. 2 TO COMMON STOCK SALES AGREEMENT November 13, 2020 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: aTyr Pharma, Inc. (the ?Company?) and H.C. Wainwright & Co., LLC (the ?Agent?) are parties to that certain Common Stock Sales Agreement dated May 21, 2019, as amended on June 18, 2019 (together, the ?Original Agreement?). All capitalized |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR |
|
| November 12, 2020 |
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37378 20-3435077 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 2, 2020 |
Up to 3,000,000 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-248905 PROSPECTUS Up to 3,000,000 Shares Common Stock This prospectus relates to the sale of up to 3,000,000 shares of our common stock by Aspire Capital Fund, LLC (Aspire Capital). Aspire Capital is also referred to in this prospectus as the selling stockholder. The prices at which the selling stockholder may sell the shares will be determined |
|
| September 24, 2020 |
CORRESP 1 filename1.htm aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 September 24, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: aTyr Pharma, Inc. Registration Statement on Form S-1 (File No. 333-248905) Request for Acceleration of Effective Date Ladies and |
|
| September 18, 2020 |
As filed with the Securities and Exchange Commission on September 18, 2020 Registration No. |
|
| September 14, 2020 |
Exhibit 99.2 IMMEDIATE RELEASE Contact: Ashlee Dunston Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO – September 14, 2020 – aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth |
|
| September 14, 2020 |
Exhibit 4.1 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 11, 2020, by and between ATYR PHARMA, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein s |
